GlaxoSmithKline plc Has Cracked Research

Why Prabhat Sakya is confident about the prospects of GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is a stalwart of the FTSE 100, and a company that we at the Fool have long recommended. But the blue chip has recently taken a strategic bend in the highway, which has made me wonder what the future holds for the pharmaceutical group.

Focusing on healthcare

When Glaxo Wellcome merged with SmithKline Beecham a decade ago, the deal was widely praised because it brought together the research-intensive ‘premium’ pharmaceutical industry with over-the-counter medicines and fast-moving consumer goods.

People have often said that GSK is a great investment because its consumer business evens out the ups and downs of the patented pharma business. I suppose people saw it as a sort of semi-Unilever, with the correspondingly higher rating.

Yet just the other week we heard that GSK has sold its Ribena and Lucozade brands to Suntory Beverage & Food Ltd.

Whilst some GSK investors may have been concerned by this sale, I see the disposal as a signal of intent. The company is simply focusing on healthcare, which has always been what GSK is really about. It still retains consumer healthcare brands such as Nicorette and Sensodyne.

Maximising its chances of success

I think the sale is a sign of the growing confidence the company has in its pharmaceutical business. I really believe that GSK has cracked healthcare research in a way no other pharmaceutical firm has.

The group focuses on its areas of strength, but also is incredibly innovative and creative. There is a strong sense of competition that drives researchers to produce their best. And there is an awareness that the company can’t produce ideas by itself, but that it needs to partner and to collaborate.

It partners with universities. It partners with small companies. And it partners with other pharmaceutical giants. By harvesting ideas from as large a field as possible, the company maximises its chances of finding the next blockbuster.

Plus it is investing in the growth areas of healthcare research: areas such as biotechnology, stem cells, vaccines and oncology.

This successful approach to innovation has resulted in a product pipeline no other pharmaceutical company can match.

For all these reasons, and despite the recent controversy about bribery in China, I am an optimist about GlaxoSmithKline’s prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Prabhat owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline and Unilever.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »